Where We Are Going Today: Moonshell

Updated 20 October 2018
0

Where We Are Going Today: Moonshell

The healthy-eating community on Instagram can affect us in many ways. Barely a day goes by without coming across a post showcasing another vegan, low-calorie food that sparks a momentary desire to quit all that junk food, because of how beautiful they make it look.
The smoothie bowl trend emerged about two years ago and has been popular on Instagram since then. Basically, you make a smoothie that is so thick in consistency that you cannot drink it through a straw, so you eat it from a bowl instead.
Moon Shell in Jeddah is a restaurant that specializes in these bowls, which are good for your health — and can make your timeline look great, too. Its smoothies are served in coconut shells and topped with your choice of fruit, nuts, seeds and chocolate.
Moon Shell also offers savory foods, including rice rolls, and a range of beverages, including coffee and matcha tea. Everything on the menu is vegan friendly. Moon Shell is the perfect place for those looking to treat themselves to truly good and nutritious food, rather than just food that tastes good but might not be the best for you. All the fruity deliciousness can be found in Rawdah district, in front of Ruf store.


Jazz Pharma’s sleep disorder treatment gets US FDA nod

Updated 21 March 2019
0

Jazz Pharma’s sleep disorder treatment gets US FDA nod

  • The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea
  • The patent of Jazz's narcolepsy drug, Xyrem, were declared invalid by a US appeals court in July
The US Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.
The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).
Solriamfetol is expected to be commercially available in the United States following the final scheduling decision by the Drug Enforcement Administration (DEA), Jazz said in a statement.
The approval comes as Jazz is trying to reduce its reliance on its blockbuster narcolepsy drug, Xyrem, whose patents were declared invalid by a US appeals court in July.
Xyrem is an approved treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. It brought in sales of $1.4 billion in 2018 and accounted for about 70 percent of company’s revenue.
“Jazz is trying to reduce its reliance on Xyrem, and solriamfetol will be one of the drugs it plans to launch to do that,” Mizuho Securities USA analyst Irina Koffler said ahead of the agency’s decision.
“Solriamfetol is expected to be an important driver of both diversification and growth,” RBC Capital Markets analyst Randall Stanicky said in a note ahead of the approval.
Solriamfetol is expected to bring in revenue of $314 million by 2024, Stanicky said.
Narcolepsy is a chronic sleep disorder with overwhelming daytime drowsiness and sudden attacks of sleep, while obstructive sleep apnea is a potentially serious sleep disorder that can cause breathing to repeatedly stop and start.
“Narcolepsy is very disabling to people as they often get diagnosed young and stop their education and drop out of high school or college,” Koffler said.
“Sleep apnea is a different problem in the sense that a lot of people don’t know they have it, have trouble breathing at night and they even fall asleep during the day.”